Oncology

Expert Insight

Story of the week

Amivantamab Plus Lazertinib vs Osimertinib for First-Line EGFR-Mutant Advanced NSCLC With Biomarkers of High-Risk Disease

Ann. Oncol; 2024 Jun 26; EPub Ahead of Print; E Felip, BC Cho, V Gutiérrez, et al

#Cancer Management #Lung #Nonsmall Cell Lung Cancer #Targeted/Biologic therapy

Short-Course vs No Androgen Deprivation Therapy Added to Postoperative Radiotherapy for Prostate Cancer

Lancet; 2024 May 16; EPub Ahead of Print; CC Parker, NW Clarke, AD Cook, et al

#Cancer Management #General Oncology #Prostate #Prostate Cancer

Commentary by Oliver Sartor MD

Long-Course vs Short-Course Androgen Deprivation Therapy Plus Postoperative Radiotherapy for Prostate Cancer

Lancet; 2024 Jun 1; 10442 (403)2416-2425; CC Parker, H Kynaston, AD Cook, et al

#Cancer Management #General Oncology #Prostate #Prostate Cancer

Commentary by Oliver Sartor MD

Amivantamab Plus Lazertinib for Previously Untreated EGFR-Mutated Advanced NSCLC

N. Engl. J. Med; 2024 Jun 26; EPub Ahead of Print; BC Cho, S Lu, E Felip, et al

#Cancer Management #Targeted/Biologic therapy

Journal Scans

Oncolytic Adenoviral Therapy Plus Pembrolizumab for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Nat. Med.; 2024 Jun 6; EPub Ahead of Print; R Li, PH Shah, TF Stewart, et al

#Bladder Cancer #Cancer Management #Genitourinary (Non-Prostate) #Targeted/Biologic therapy

Commentary by Prof. Dr. Alexander van Akkooi MD, PhD

Clinical Impact of Mutated JAK2 Allele Burden Reduction in Patients With Polycythemia Vera and Essential Thrombocythemia

Am. J. Hematol; 2024 Jun 6; EPub Ahead of Print; P Guglielmelli, B Mora, F Gesullo, et al

#Hematology

Commentary by Hannah Goulart MD & Sanam Loghavi MD

Epcoritamab Monotherapy for Relapsed or Refractory Follicular Lymphoma

Lancet Haematol; 2024 Jun 13; EPub Ahead of Print; KM Linton, U Vitolo, W Jurczak, et al

#Cancer Management #General Oncology #Hematology #Lymphomas #Non-Hodgkin's Lymphoma

Brigatinib in Patients With NF2-Related Schwannomatosis With Progressive Tumors

N. Engl. J. Med; 2024 Jun 27; 390 (24)2284-2294; SR Plotkin, KH Yohay, PL Nghiemphu, et al

#CNS/Brain

Crovalimab vs Eculizumab for Complement Inhibition–Naïve Paroxysmal Nocturnal Hemoglobinuria

Am. J. Hematol; 2024 Jun 17; EPub Ahead of Print; A Röth, G He, H Tong, et al

#Hematology

Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Refractory EGFR-Mutated NSCLC

J. Clin. Oncol; 2024 Jun 10; EPub Ahead of Print; NB Leighl, H Akamatsu, SM Lim, et al

#Lung

Upfront FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer

J. Clin. Oncol; 2024 Jun 12; EPub Ahead of Print; C Antoniotti, D Rossini, F Pietrantonio, et al

#Colon and Rectum